within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA02_Teicoplanin;

model Teicoplanin
  extends Pharmacolibrary.Drugs.ATC.J.J01XA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01XA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Teicoplanin is a glycopeptide antibiotic effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is used primarily for serious infections caused by susceptible organisms, including bone and joint infections, endocarditis, and bacteremia, particularly in hospital settings. It is approved and used clinically in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following intravenous administration of teicoplanin. Two-compartment model.</p><h4>References</h4><ol><li><p>Jumpertz, M, et al., &amp; Cassir, N (2022). Subcutaneously administered antibiotics: a review. <i>The Journal of antimicrobial chemotherapy</i> 78(1) 1–7. DOI:<a href=\"https://doi.org/10.1093/jac/dkac383\">10.1093/jac/dkac383</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36374566/\">https://pubmed.ncbi.nlm.nih.gov/36374566</a></p></li><li><p>Rybak, MJ, et al., &amp; Yuh, L (1991). Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. <i>Antimicrobial agents and chemotherapy</i> 35(4) 696–700. DOI:<a href=\"https://doi.org/10.1128/AAC.35.4.696\">10.1128/AAC.35.4.696</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1829880/\">https://pubmed.ncbi.nlm.nih.gov/1829880</a></p></li><li><p>Rowland, M (1990). Clinical pharmacokinetics of teicoplanin. <i>Clinical pharmacokinetics</i> 18(3) 184–209. DOI:<a href=\"https://doi.org/10.2165/00003088-199018030-00002\">10.2165/00003088-199018030-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2138946/\">https://pubmed.ncbi.nlm.nih.gov/2138946</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Teicoplanin;
